WDB coco Co., Ltd. (7079) AI Stock Analysis

• Market Cap: ¥6.56B
• Dividend Yield: 2.93%
• Average Volume (3M): 5.76K
• Price to Earnings (P/E): 7.9
• Beta (1Y): 0.63
• Revenue Growth: 9.77%
• EPS Growth: -10.78%
• Country: JP
• Employees: 504
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 67.98
• Shares Outstanding: 2,405,000
• 10 Day Avg. Volume: 2,120
• 30 Day Avg. Volume: 5,756
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: ¥3,214.00
• Price Target Upside: 17.77% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1

• Rating: 74 Outperform
• Price Target: ¥3,214.00 ▲(17.77% Upside)

WDB coco Co., Ltd. scores highly due to its strong financial performance, characterized by robust revenue and profit growth, effective cost management, and excellent cash flow generation. The valuation is favorable, with a low P/E ratio and attractive dividend yield. However, technical indicators suggest a bearish trend, which slightly offsets the overall score.

WDB coco Co., Ltd. Business Overview & Revenue Model

Company Description

WDB coco Co., Ltd. (7079) is a company that operates within the healthcare and clinical sectors. It provides various services related to clinical development, primarily focusing on offering support and solutions for clinical trials and related research activities. The company serves pharmaceutical companies, biotechnology firms, and other organizations engaged in drug development and healthcare research.

How the Company Makes Money

WDB coco Co., Ltd. generates revenue through its comprehensive suite of services designed to support clinical trials and research. The company's primary revenue streams include fees charged for consulting, project management, and operational support services provided to clients in the pharmaceutical and biotechnology sectors. These services are crucial for the planning, execution, and management of clinical trials. Additionally, WDB coco Co., Ltd. may partner with other organizations or engage in collaborations that expand its service offerings and client base, further enhancing its revenue potential.

WDB coco Co., Ltd. Financial Statement Overview

Summary

WDB coco Co., Ltd. exhibits strong financial performance with impressive revenue and profit growth, supported by robust margins and effective cost management. The balance sheet is healthy, with low leverage and strong equity growth. Cash flow management is excellent, with consistent free cash flow generation. While liabilities have increased, the overall financial health remains strong.

Income Statement

WDB coco Co., Ltd. shows strong and consistent revenue growth with a notable increase from ¥2.57 billion in 2021 to ¥5.33 billion in 2025. Gross profit margin remains robust, averaging around 39% over the years, indicating effective cost management. The net profit margin has improved from 14.5% in 2021 to 17.1% in 2025, showcasing enhanced profitability. EBIT and EBITDA margins are also healthy, reflecting efficient operations. Overall, the income statement reflects strong growth and profitability.

Balance Sheet

The company's balance sheet is solid, with a low debt-to-equity ratio, indicating minimal leverage risk. Stockholders' equity has grown significantly, reflecting strong financial health. The equity ratio is high, suggesting a stable financial structure. However, the total liabilities have increased, which should be monitored. Overall, the balance sheet reflects strong financial stability and low leverage.

Cash Flow

WDB coco Co., Ltd. demonstrates strong cash flow management, with consistent growth in operating and free cash flows. The free cash flow to net income ratio is high, indicating efficient cash generation relative to earnings. The operating cash flow to net income ratio is also strong, reflecting effective cash management. The company has maintained positive free cash flow growth, underscoring its ability to generate cash beyond its operational needs.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	5.33B	5.33B	4.60B	4.07B	3.62B	2.57B
Gross Profit	2.08B	2.08B	1.94B	1.59B	1.44B	903.33M
EBITDA	1.34B	1.37B	1.31B	1.12B	978.74M	538.66M
Net Income	912.77M	912.90M	857.83M	743.63M	647.70M	373.18M
Balance Sheet
Total Assets	5.59B	5.59B	4.66B	3.66B	3.13B	2.13B
Cash, Cash Equivalents and Short-Term Investments	3.48B	3.48B	2.66B	2.00B	1.89B	1.28B
Total Debt	29.81M	29.81M	27.12M	24.32M	33.52M	19.97M
Total Liabilities	1.29B	1.29B	1.10B	858.14M	985.59M	564.02M
Stockholders Equity	4.30B	4.30B	3.56B	2.80B	2.15B	1.57B
Cash Flow
Free Cash Flow	0.00	1.10B	684.97M	452.26M	706.12M	291.89M
Operating Cash Flow	0.00	1.10B	772.20M	517.49M	747.90M	293.93M
Investing Cash Flow	0.00	-88.33M	-91.82M	-302.97M	-60.48M	-1.92M
Financing Cash Flow	0.00	-195.83M	-110.94M	-101.21M	-79.11M	-42.87M

WDB coco Co., Ltd. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 2729.00
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:7079, the sentiment is Negative. The current price of 2729 is below the 20-day moving average (MA) of 2776.05, below the 50-day MA of 2859.08, and below the 200-day MA of 3182.12, indicating a bearish trend. The MACD of -31.74 indicates Negative momentum. The RSI at 40.55 is Neutral, neither overbought nor oversold. The STOCH value of 39.75 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:7079.

WDB coco Co., Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
7079	74 Outperform	¥6.56B	7.91		2.93%	9.77%	-10.78%
4582	51 Neutral	7.03B	-1.43	0.00%	―	-50.88%	-22.14%
4892	44 Neutral	5.70B	-5.95	-34.31%	―	8.12%	-19.12%
4586	41 Neutral	5.88B	-3.47	0.00%	―	-82.19%	-106.15%
4883	39 Underperform	6.35B	-3.56	0.00%	―	0.00%	64.87%
4597	37 Underperform	9.02B	-4.05	0.00%	―	84.28%	-17.32%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%